Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7644MR)

This product GTTS-WQ7644MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7644MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1242MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ3593MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ6563MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ1198MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ14707MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ4606MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ2474MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ10451MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2541546
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW